Windlas Biotech Limited (NSE:WINDLAS) informed stock exchanges on 10 August 2026 that its Board of Directors approved unaudited standalone financial results for the quarter ended 30 June 2026, with revenue from operations reaching Rs 2,480.99 million and profit after tax of Rs 176.53 million.
Key Highlights
- Standalone revenue from operations for Q1 FY27 rose to Rs 2,480.99 million, compared with Rs 2,100.90 million in Q1 FY26, reflecting year-on-year growth.
- Profit after tax for Q1 FY27 stood at Rs 176.53 million, broadly in line with Rs 176.65 million reported in the corresponding quarter of the previous year.
- Basic earnings per share for Q1 FY27 were Rs 8.46 and diluted EPS were Rs 8.32, on a face value of Rs 5 per share; these figures are not annualised.
- The wholly owned non-operating subsidiary Windlas Inc., USA was dissolved with effect from 31 March 2026, and consolidated financial statements will no longer be prepared from 1 April 2026 onwards.
About the Company
Windlas Biotech Limited (NSE:WINDLAS), headquartered in Dehradun, Uttarakhand with a corporate office in Gurugram, Haryana, is a pharmaceutical contract development and manufacturing organisation. The company operates in a single reportable segment, Pharmaceuticals, and provides formulation development, manufacturing, and supply chain services to domestic and international pharma brands from its Uttarakhand-based manufacturing facilities.
Announcement in Detail
The Board meeting convened on 10 August 2026 between 2:30 PM and 3:15 PM, during which directors approved unaudited standalone results for Q1 FY27 under Regulation 33 of SEBI (LODR) Regulations, 2015. Total income for the quarter was Rs 2,532.12 million against Rs 2,153.29 million a year earlier. Total expenses rose to Rs 2,302.76 million, with cost of materials consumed at Rs 1,687.41 million and employee benefit expenses at Rs 444.34 million. Profit before tax came in at Rs 229.36 million.
The filing also disclosed that the company completed a buyback of 470,000 equity shares at Rs 1,000 per share via the Tender Offer route, totalling Rs 470 million, reducing paid-up share capital to 20,636,229 shares of Rs 5 face value each. Additionally, the Board had proposed a dividend of Rs 6.30 per share for FY26, which shareholders approved at the AGM held on 23 July 2026; the aggregate payout of Rs 130.01 million was disbursed on 31 July 2026. Share-based payment expense recognised during Q1 FY27 was Rs 71.62 million.
Impact on Investors
Investors will note that Q1 FY27 profit after tax of Rs 176.53 million was marginally below the Rs 176.65 million recorded in Q1 FY26, while revenue expanded meaningfully year-on-year. The disclosed terms indicate that the completed buyback has reduced the outstanding share count to 20,636,229 equity shares, which shareholders will observe adjusts per-share metrics relative to the prior capital base.
The filing shows that following the dissolution of Windlas Inc., USA effective 31 March 2026, the company no longer prepares consolidated financial statements from 1 April 2026, meaning future disclosures will be on a standalone basis only. Investors reviewing continuity of financial comparisons should account for this structural change in reporting scope.
Sector / Market Context
India's pharmaceutical contract manufacturing sector has grown as domestic and multinational drug companies increasingly outsource formulation production. According to the Indian Pharmaceutical Alliance and FICCI, India remains one of the largest generic medicine suppliers globally by volume. Contract development and manufacturing organisations operating out of Uttarakhand benefit from historical fiscal incentives that shaped manufacturing cluster development in the region, providing a stable operating base for companies such as Windlas Biotech.